Sanyal 2025 — ESSENCE MASH Semaglutide

New England Journal of Medicine·April 30, 2025

Arun J. Sanyal, Philip N. Newsome, et al.

Summary

62.9% achieved resolution of steatohepatitis vs 34.3% placebo. 36.8% achieved fibrosis improvement vs 22.4% placebo. FDA approved August 2025.

Study Details

Study Design

Phase 3, multicenter, randomized, double-blind, placebo-controlled trial

Indication

MASH with fibrosis stage 2 or 3

Intervention

Semaglutide 2.4 mg weekly vs placebo

Species

Human

Sample Size

1,197 subjects